Newco
-
The Three Fates of Newco and the Birth of LIDNewco
LIDNewCo=License In-Development-NewCo model, is the 2.0 version of NewCo
-
进军全球最大的美国市场？美国本土团队助您一臂之力！
欢迎联系药时代！我们的联系邮箱是：consulting@drugtimes.cn
-
>$600M! Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Congratulations! This is the latest successful case of NewCo for China pharma and biotech companies
-
超6亿美元！维立志博与Aditum Bio合作成立Oblenio Bio，全力推进自免领域三特异性T细胞衔接器研发
热烈祝贺！NewCo模式的最新成功案例
-
The biggest biotech financing of the year has been born! Who will be the next “buyer”?
What will be the fate of this new player in autoimmune diseases in the future?
